Page 786 - Read Online

Page 12 of 14 Stolz et al. Mini-invasive Surg 2020;4:76 I http://dx.doi.org/10.20517/2574-1225.2020.69

7. Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST
II study. J Am Coll Cardiol 2014;64:172-81.
8. Bonow RO, O’Gara PT, Adams DH, et al. 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the
Management of Mitral Regurgitation: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll
Cardiol 2020;75:2236-70.
9. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J
2017;38:2739-91.
10. Marmagkiolis K, Hakeem A, Ebersole DG, et al. Clinical outcomes of percutaneous mitral valve repair with MitraClip for the
management of functional mitral regurgitation. Catheter Cardiovasc Interv 2019;94:820-6.
11. Praz F, Braun D, Unterhuber M, et al. Edge-to-edge mitral valve repair with extended clip arms: early experience from a multicenter
observational study. JACC Cardiovasc Interv 2019;12:1356-65.
12. Obadia JF, Messika-Zeitoun D, Leurent G, et al; MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral
regurgitation. N Engl J Med 2018;379:2297-306.
13. Stone GW, Lindenfeld J, Abraham WT, et al; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N
Engl J Med 2018;379:2307-18.
14. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that
reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging 2019;12:353-62.
15. Mauricio R, Kumbhani DJ. MitraClip: how do we reconcile the inconsistent findings of MITRA-FR and COAPT? Curr Cardiol Rep
2019;21:150.
16. Luc JGY, Hong JC, Cheung AW, et al. The MITRA-FR trial vs the COAPT trial: more complementary than contradictory? Ann Thorac
Surg 2019;108:965-8.
17. Gaasch WH, Aurigemma GP, Meyer TE. An appraisal of the association of clinical outcomes with the severity of regurgitant volume
relative to end-diastolic volume in patients with secondary mitral regurgitation. JAMA Cardiol 2020;5:476-81.
18. Adamo M, Cani DS, Gavazzoni M, et al. Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge
percutaneous mitral valve repair. EuroIntervention 2020;16:413-20.
19. Orban M, Karam N, Lubos E, et al; EuroSMR Investigators. Impact of proportionality of secondary mitral regurgitation on outcome after
transcatheter mitral valve repair. JACC Cardiovasc Imaging 2020:S1936-878X(20)30620-3.
20. Ben-Shoshan J, Overtchook P, Buithieu J, et al. Predictors of outcomes following transcatheter edge-to-edge mitral valve repair. JACC
Cardiovasc Interv 2020;13:1733-48.
21. Zanolla L, Zardini P. Selection of endpoints for heart failure clinical trials. Eur J Heart Fail 2003;5:717-23.
22. Anker SD, Schroeder S, Atar D, et al. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive
efficacy assessments and improving trial efficiency. Eur J Heart Fail 2016;18:482-9.
23. Fiuzat M, Lowy N, Stockbridge N, et al. Endpoints in heart failure drug development: history and future. JACC Heart Fail 2020;8:429-
40.
24. Stone GW, Adams DH, Abraham WT, et al; Mitral Valve Academic Research Consortium (MVARC). Clinical trial design principles and
endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions a consensus document from the
mitral valve academic research consortium. J Am Coll Cardiol 2015;66:308-21.
25. Orban M, Orban M, Lesevic H, et al. Predictors for long-term survival after transcatheter edge-to-edge mitral valve repair. J Interv
Cardiol 2017;30:226-33.
26. Braun D, Lesevic H, Orban M, et al. Percutaneous edge-to-edge repair of the mitral valve in patients with degenerative versus functional
mitral regurgitation. Catheter Cardiovasc Interv 2014;84:137-46.
27. Öztürk C, Friederich M, Werner N, et al. Single-center five-year outcomes after interventional edge-to-edge repair of the mitral valve.
Cardiol J 2019; doi: 10.5603/CJ.a2019.0071.
28. Sürder D, Klersy C, Corti R, et al; Collaborators. Impact of mitral regurgitation aetiology on MitraClip outcomes: the MitraSwiss registry.
EuroIntervention 2020;16:e112-20.
29. Dörr O, Walther C, Liebetrau C, et al. Galectin-3 and ST2 as predictors of therapeutic success in high-risk patients undergoing
percutaneous mitral valve repair (MitraClip). Clin Cardiol 2018;41:1164-9.
30. Thaden JJ, Malouf JF, Nkomo VT, et al. Mitral valve anatomic predictors of hemodynamic success with transcatheter mitral valve repair.
J Am Heart Assoc 2018;7:e007315.
31. Oguz D, Eleid MF, Dhesi S, et al. Quantitative three-dimensional echocardiographic correlates of optimal mitral regurgitation reduction
during transcatheter mitral valve repair. J Am Soc Echocardiogr 2019;32:1426-35.e1.
32. Tabata N, Weber M, Sugiura A, et al. Impact of the leaflet-to-annulus index on residual mitral regurgitation in patients undergoing edge-
to-edge mitral repair. JACC Cardiovasc Interv 2019;12:2462-72.
33. Reichart D, Kalbacher D, Rübsamen N, et al. The impact of residual mitral regurgitation after MitraClip therapy in functional mitral
regurgitation. Eur J Heart Fail 2020; doi: 10.1002/ejhf.1774.
34. Bozdag-Turan I, Paranskaya L, Birkemeyer R, et al. Percutaneous mitral repair with the MitraClip system in patients with mild-to-
moderate and severe heart failure: a single-centre experience. Cardiovasc Ther 2014;32:66-73.
35. Adamo M, Grasso C, Capodanno D, et al. Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from
the multicenter GRASP-IT registry. Am Heart J 2019;217:32-41.
36. Paranskaya L, D’Ancona G, Bozdag-Turan I, et al. Early and mid-term outcomes of percutaneous mitral valve repair with the MitraClip®: